Abbott Laboratories $ABT Shares Purchased by Hill Island Financial LLC

Hill Island Financial LLC raised its stake in Abbott Laboratories (NYSE:ABT) by 38.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,124 shares of the healthcare product maker’s stock after purchasing an additional 863 shares during the quarter. Hill Island Financial LLC’s holdings in Abbott Laboratories were worth $425,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ABT. Brighton Jones LLC increased its stake in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after acquiring an additional 4,755 shares during the last quarter. First National Corp MA ADV increased its position in Abbott Laboratories by 1.1% during the 1st quarter. First National Corp MA ADV now owns 11,270 shares of the healthcare product maker’s stock worth $1,495,000 after purchasing an additional 123 shares in the last quarter. Impact Capital Partners LLC raised its holdings in Abbott Laboratories by 3.9% in the first quarter. Impact Capital Partners LLC now owns 21,810 shares of the healthcare product maker’s stock valued at $2,893,000 after buying an additional 826 shares during the period. Congress Asset Management Co. lifted its position in Abbott Laboratories by 6.3% during the first quarter. Congress Asset Management Co. now owns 3,529 shares of the healthcare product maker’s stock valued at $468,000 after buying an additional 210 shares in the last quarter. Finally, Sara Bay Financial grew its stake in Abbott Laboratories by 9.2% during the first quarter. Sara Bay Financial now owns 8,416 shares of the healthcare product maker’s stock worth $1,101,000 after buying an additional 709 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $134.49 on Friday. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The business has a 50 day moving average price of $131.94 and a two-hundred day moving average price of $131.36. The firm has a market cap of $234.07 billion, a PE ratio of 16.85, a price-to-earnings-growth ratio of 2.55 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. During the same period in the prior year, the business posted $1.14 EPS. The business’s revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories’s payout ratio is presently 29.57%.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Morgan Stanley lifted their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Jefferies Financial Group upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Leerink Partners initiated coverage on Abbott Laboratories in a research note on Monday, June 16th. They issued a “market perform” rating and a $143.00 target price for the company. The Goldman Sachs Group boosted their price target on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Wells Fargo & Company lowered their price objective on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research report on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.39.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.